Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
Related Posts
Shah PD, Yeremian S, Forte E, Park D, Choi E, Qi J, Nguyen A, Akhtari M. EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications[...]
Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, Rutkowski P, Rivalland G, Ribas A, Mehnert JM, Ott PA, Dummer R, Queirolo[...]
Garassino MC, Ahn MJ, Schick M, Kapil A, Paz-Ares L, Lisberg A, Johnson ML, Pérol M, Shimizu T, Heist R, Spira A, Okamoto I, Girard[...]